(Q39527903)

English

Zyflamend inhibits the expression and function of androgen receptor and acts synergistically with bicalutimide to inhibit prostate cancer cell growth

scientific article published on 8 June 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Zyflamend inhibits the expression and function of androgen receptor and acts synergistically with bicalutimide to inhibit prostate cancer cell growth (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

prostate cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Jun Yan

1

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Bingxian Xie

2

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Jillian L Capodice

3

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Aaron E Katz

4

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

publication date

8 June 2011

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

72

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

244-252

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21426

21 January 2018

Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21426

21 January 2018

Steroid receptor coactivator-3/AIB1 promotes cell migration and invasiveness through focal adhesion turnover and matrix metalloproteinase expression

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21426

21 January 2018

Mechanisms of androgen-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21426

21 January 2018

The utility of 5-alpha reductase inhibitors in the prevention and diagnosis of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21426

21 January 2018

Overview of pivotal studies for prostate cancer risk reduction, past and present

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21426

21 January 2018

Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling?

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21426

21 January 2018

Zyflamend, a unique herbal preparation with nonselective COX inhibitory activity, induces apoptosis of prostate cancer cells that lack COX-2 expression

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21426

21 January 2018

Zyflamend-mediated inhibition of human prostate cancer PC3 cell proliferation: effects on 12-LOX and Rb protein phosphorylation

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21426

21 January 2018

Zyflamend reduces LTB4 formation and prevents oral carcinogenesis in a 7,12-dimethylbenz[alpha]anthracene (DMBA)-induced hamster cheek pouch model.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21426

21 January 2018

Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21426

21 January 2018

Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21426

21 January 2018

Prostate-specific antigen doubling time as a prognostic marker in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21426

21 January 2018

Resveratrol-induced gene expression profiles in human prostate cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21426

21 January 2018

Repressive effects of resveratrol on androgen receptor transcriptional activity

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21426

21 January 2018

Differential effects of resveratrol on androgen-responsive LNCaP human prostate cancer cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21426

21 January 2018

Epigallocatechin-3-Gallate suppresses early stage, but not late stage prostate cancer in TRAMP mice: mechanisms of action.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21426

21 January 2018

Curcumin downregulates homeobox gene NKX3.1 in prostate cancer cell LNCaP.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21426

21 January 2018

Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21426

21 January 2018

Chemoprevention of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21426

21 January 2018

Identifiers

10.1002/PROS.21426

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39527903&oldid=2164735906"